Tecvayli (Teclistamab) Demonstrates Positive Results in MajesTEC-5 and MajesTEC-4 Trials
CompanyDrug

Tecvayli (Teclistamab) Demonstrates Positive Results in MajesTEC-5 and MajesTEC-4 Trials

SinoPep-Allsino Biopharmaceutical Partners with Spraying Systems Co. for Peptide API Manufacturing
CompanyDeals

SinoPep-Allsino Biopharmaceutical Partners with Spraying Systems Co. for Peptide API Manufacturing

Merck's Zilovertamab Vedotin Shows 100% CR Rate in Phase II Study for DLBCL: ASH Presentation
CompanyDrug

Merck’s Zilovertamab Vedotin Shows 100% CR Rate in Phase II Study for DLBCL: ASH Presentation

Medtide Inc. Submits Second IPO Application to Hong Kong Stock Exchange
CompanyDeals

Medtide Inc. Submits Second IPO Application to Hong Kong Stock Exchange

AstraZeneca's Calquence Combo Shows 35% Reduced Risk in CLL: AMPLIFY Phase III Results
CompanyDrug

AstraZeneca’s Calquence Combo Shows 35% Reduced Risk in CLL: AMPLIFY Phase III Results

Abbisko Therapeutics Presents Positive Phase II Results for Pimicotinib in cGvHD at ASH
CompanyDrug

Abbisko Therapeutics Presents Positive Phase II Results for Pimicotinib in cGvHD at ASH

Jacobio Pharma's BET Inhibitor JAB-8263 Shows Promising Results in Myelofibrosis Phase I Study
CompanyDrug

Jacobio Pharma’s BET Inhibitor JAB-8263 Shows Promising Results in Myelofibrosis Phase I Study

Youcare Pharmaceutical Gets FDA Clearance for Herpes Zoster mRNA Vaccine YKYY026
CompanyDrug

Youcare Pharmaceutical Gets FDA Clearance for Herpes Zoster mRNA Vaccine YKYY026

Duality Biologics' DB-1311 ADC Shows Promising Results in Global Phase 1/2a Trial
CompanyDrug

Duality Biologics’ DB-1311 ADC Shows Promising Results in Global Phase 1/2a Trial

Chipscreen Biosciences' Chiauranib Phase III Trial Results for SCLC Announced
CompanyDrug

Chipscreen Biosciences’ Chiauranib Phase III Trial Results for SCLC Announced

Immunofoco's IMC002 CAR-T Therapy Receives FDA Fast Track Designation for Gastric Cancer
CompanyDrug

Immunofoco’s IMC002 CAR-T Therapy Receives FDA Fast Track Designation for Gastric Cancer

Shanghai Juncell Therapeutics has announced that the National Medical Products Administration's Center for Drug Evaluation (CDE) has approved the first pivotal Phase II registration clinical trial for its GC101 TIL injection. The trial, designated as NCT06703398, is for the treatment of advanced melanoma patients who have progressed or are intolerant to PD-1 antibody therapy. The study will be led by Professor Guo Jun, a global authority in melanoma treatment at Beijing Cancer Hospital, and will be conducted as a multicenter clinical research across China.
CompanyDrug

Shanghai Juncell Therapeutics’ GC101 TIL Therapy Receives CDE Approval for Pivotal Phase II Trial